RNTX
RNTX
NASDAQ · Biotechnology

Rein Therapeutics Inc

$1.25
-0.02 (-1.57%)
Financial Highlights (FY 2025)
Revenue
47.89M
Net Income
949.8K
Gross Margin
48.8%
Profit Margin
2.0%
Rev Growth
-0.9%
D/E Ratio
0.33
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 48.8% 48.8% 48.8%
Operating Margin 2.7% 2.7% 2.3%
Profit Margin 2.0% 1.8% 1.5%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 47.89M 42.94M 46.10M
Gross Profit 23.36M 20.95M 22.49M
Operating Income 1.31M 1.14M 1.08M
Net Income 949.8K 770.7K 699.4K
Gross Margin 48.8% 48.8% 48.8%
Operating Margin 2.7% 2.7% 2.3%
Profit Margin 2.0% 1.8% 1.5%
Rev Growth -0.9% +8.9% +4.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 5.62M 6.92M 6.69M
Total Equity 16.94M 17.73M 15.71M
D/E Ratio 0.33 0.39 0.43
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 1.44M 1.43M 1.37M
Free Cash Flow 717.1K 500.4K 604.2K